FLT3 Fusion is an inclusion criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain FLT3 Fusion and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FLT3 Fusion and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain FLT3 Fusion and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FLT3 Fusion is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FLT3 Fusion and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain FLT3 Fusion and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [5].

FLT3 Fusion is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain FLT3 Fusion and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FLT3 Fusion and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and cancer as inclusion criteria, 1 is phase 2 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 Fusion and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

FLT3 Fusion is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 Fusion and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].